Csop Hang Seng Tech Index ETF(03033.HK) Rose 1.14% to 5.045
Newtimespace News, as of 10:36 on May 14, Csop Hang Seng Tech Index ETF(03033.HK) was quoted at HKD 5.045, up 1.14%. The ETF opened at HKD 5.140, with a high of HKD 5.145 and a low of HKD 5.020. The latest NAV per unit is HKD 4.983, with a premium rate of 0.10%. The asset size is approximately HKD 87.245 billion.
Csop Hang Seng Tech Index ETF(03033.HK) tracks the Hang Seng Tech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to reflect the performance of leading companies listed in Hong Kong that are highly related to the technology theme, covering companies in sectors such as the internet, fintech, cloud services, and e-commerce. It serves as one of the key market benchmarks for gauging the performance of Hong Kong's technology sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HATCHER GROUP (08365.HK): Shareholder Buys Back 36% Stake in Target Company for HKD 1, Cutting Group's Stake to 15%; Target Signs Strategic Investment LOI for Low-Altitude Economy Project
- C HEALTH GP (08225.HK): Provides Update on Receivables Recovery; Applies to Set Aside Rejected Arbitration Award against Related Party, Collects RMB 2.088 Million from Cooperative Customers since June
- VGT (02476.HK): Third-Level Wholly-Owned Subsidiaries Sign Maximum Guarantee Agreements, Providing Mutual Guarantees of RMB 30 Million within Annual Guarantee Limit
- VIVA GOODS (00933.HK): Acquires Further 17,253,500 Li Ning Shares on Open Market for about HKD 228,207,000; Stake to Rise to about 17.58%
- OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China